Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia

Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia

“…These results are in line with published results of the Italian study group treating patients with NILG‐ALL 09/00 protocol . MRD value measured at week 10 was prognostically decisive as patients who had MRD <10 −4 at this time point had 5‐yr OS and DFS 75% and 72% (vs. 33% and 14% in MRD ≥10 −4 ) . This is in concordance with the GRAAL study showing that high‐risk patients whose MRD dropped to <10 −4 at week 6 did not benefit from allogeneic HSCT .…”

“…Several studies have shown that age and minimal residual disease (MRD) are the most powerful prognostic factors in adult ALL (5)(6)(7)(8)(9)(10). MRD is not only a measure of individual sensitivity to the given therapy.…”

Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy

“…Although our results as well as those from other studies [5,13] would not support this suggestion, it is probable that the pattern of minimal residual disease (MRD) clearance should ultimately be the key criterion for decision to perform transplantation or to include these patients into clinical trials with new therapies (eg, immunologically-based) as is currently done in recent adult ALL trials [12,20,21].…”

Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia

“…Indeed, MRD‐positive patients who receive HSCT tend to experience better outcomes than those who do not . Furthermore, patients who are MRD‐positive before HSCT may be more likely to relapse and have poorer outcomes after transplantation than those who are MRD‐negative before HSCT …”

“…7,9,22,26,27 Furthermore, patients who are MRD-positive before HSCT may be more likely to relapse and have poorer outcomes after transplantation than those who are MRD-negative before HSCT. 22,[28][29][30][31][32] To understand the prognostic implications of MRD in real-world clinical practice, a retrospective study of adult MRD-positive patients who received standard-of-care (SOC) treatment between 2000 and 2014 was recently conducted using European ALL study group databases. 33 Median relapse-free survival (RFS) was 12.4 months (95% confidence interval [CI]: 10.0-19.0), and median overall survival (OS) was 32.5 months (95% CI: 23.6-48.0) from baseline MRD detection in the historic data set among patients in first CR.…”